daltland on DSKBBV9HB2PROD with NOTICES

3748 Federal Register / Vol. 83, No. 18 / Friday, January 26, 2018 / Notices 

Schedule I of the 1961 Single 

Convention. 

5F–ADB is a clandestinely produced 

synthetic cannabinoid agonist. In 

general, adverse effects produced by 

cannabinoid agonists include 

tachycardia, agitation, hallucination, 

chest pain, seizure, anxiety, and acute 

psychosis. 5F–ADB has been identified 

in overdose and/or cases involving 

death attributed to their abuse. Adverse 

health effects reported from incidents 

involving 5F–ADB and other synthetic 

cannabinoids have included: nausea, 

persistent vomiting, agitation, altered 

mental status, seizures, convulsions, 

loss of consciousness, and/or cardio 

toxicity. On April 10, 2017, the DEA 

issued a temporary scheduling order to 

temporarily schedule 5F–ADB, its 

isomers, esters, ethers, salts and salts of 

isomers, esters, and ethers into 

Schedule I pursuant to the temporary 

scheduling provisions of the CSA (82 FR 

17119). As such, additional permanent 

controls will be necessary to fulfill U.S. 

obligations if 5F–ADB is controlled 

under Schedule II of the 1971 

Convention on Psychotropic 

Substances. 

AB–PINACA is a clandestinely 

produced synthetic cannabinoid agonist 

approximately 1.5 times as potent as 

delta-9-tetrahydrocannabinol. Adverse 

effects produced by cannabinoid 

agonists include tachycardia, agitation, 

hallucination, chest pain, seizure, 

anxiety, acute psychosis, and death. 

AB–PINACA has been detected in illicit 

synthetic cannabinoid substances, and 

reported in cases of overdose and 

hospitalizations. It has not been 

approved for medical use in the United 

States. On October 16, 2017, the DEA 

published a Final Rule to permanently 

control AB–PINACA as a Schedule I 

substance under the CSA (82 FR 47971). 

As such, additional permanent controls 

will not be necessary to fulfill U.S. 

obligations if AB–PINACA is controlled 

under Schedule II of the 1971 

Convention on Psychotropic 

Substances. 

UR–144 is a clandestinely produced 

synthetic cannabinoid agonist. In 

general, adverse effects produced by 

cannabinoid agonists include 

tachycardia, agitation, hallucination, 

chest pain, seizure, anxiety, acute 

psychosis, and death. UR–144 has been 

detected in herbal smoking blends that 

are sold as herbal incense. On May 11, 

2016, the DEA issued a Final Rule to 

permanently schedule UR–144 into 

Schedule I of the CSA (81 FR 29142). As 

such, additional permanent controls 

will not be necessary to fulfill U.S. 

obligations if UR–144 is controlled 

under Schedule II of the 1971 

Convention on Psychotropic 

Substances. 

5F–PB–22 is a synthetic cannabinoid 

agonist with similar effects to delta-9-

tetrahydrocannabinol, one of the main 

psychoactive components of cannabis. 

Adverse effects produced by 

cannabinoid agonists include 

tachycardia, agitation, hallucination, 

chest pain, seizure, anxiety, acute 

psychosis, and death. 5F–PB–22 is 

clandestinely produced. It has been 

found laced on plant material and 

marketed as herbal products, and is 

smoked for its psychoactive effects. 

According to the WHO, 5F–PB–22 has 

been associated with fatal intoxications. 

On September 6, 2016, the DEA issued 

a Final Rule to permanently place 5F– 

PB–22 into Schedule I of the CSA (81 

FR 61130). As such, additional 

permanent controls will not be 

necessary to fulfill U.S. obligations if 

5F–PB–22 is controlled under Schedule 

II of the 1971 Convention on 

Psychotropic Substances. 

4-Fluoroamphetamine (4–FA) is a 

psychoactive substance of the 

phenethylamine and substituted 

amphetamine chemical classes and 

produces stimulant effects. WHO 

reports that 4–FA is clandestinely 

produced, and its use is associated with 

fatal and non-fatal intoxications. 4–FA 

is not approved for medical use in the 

United States and it is not controlled 

under the CSA. As such, additional 

permanent controls will be necessary to 

fulfill U.S. obligations if 4–FA is 

controlled under Schedule II of the 1971 

Convention on Psychotropic 

Substances. 

FDA, on behalf of the Secretary of 

HHS, invites interested persons to 

submit comments on the notifications 

from the United Nations concerning 

these drug substances. FDA, in 

cooperation with the National Institute 

on Drug Abuse, will consider the 

comments on behalf of HHS in 

evaluating the WHO scheduling 

recommendations. Then, under section 

201(d)(2)(B) of the CSA, HHS will 

recommend to the Secretary of State 

what position the United States should 

take when voting on the 

recommendations for control of 

substances under the Psychotropic 

Convention at the CND meeting in 

March 2018. 

Comments regarding the WHO 

recommendations for control of 

carfentanil, ocfentanil, furanyl fentanyl 

(Fu-F), acryloylfentanyl (acryl fentanyl), 

4-fluoroisobutyryl fentanyl (4–FIBF), 

and tetrahydrofuranylfentanyl (THF–F), 

under the 1961 Single Convention, will 

also be forwarded to the relevant 

Agencies for consideration in 

developing the U.S. position regarding 

narcotic substances at the CND meeting. 

Dated: January 23, 2018. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2018–01471 Filed 1–25–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Final Effect of Designation of a Class 

of Employees for Addition to the 

Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HHS gives notice concerning 

the final effect of the HHS decision to 

designate a class of employees from the 

Idaho National Laboratory in Scoville, 

Idaho, as an addition to the Special 

Exposure Cohort (SEC) under the Energy 

Employees Occupational Illness 

Compensation Program Act of 2000. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

NIOSH, 1090 Tusculum Avenue, MS C– 

46, Cincinnati, OH 45226–1938, 

Telephone 877–222–7570. Information 

requests can also be submitted by email 

to DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: 

Authority: 42 U.S.C. 7384q(b). 42 U.S.C. 

7384l(14)(C). 

On November 22, 2017, as provided 

for under 42 U.S.C. 7384l(14)(C), the 

Acting Secretary of HHS designated the 

following class of employees as an 

addition to the SEC: 

All employees of the Department of 

Energy, its predecessor agencies, and their 

contractors and subcontractors who worked 

at the Idaho National Laboratory (INL) in 

Scoville, Idaho, and who were monitored for 

external radiation at the Idaho Chemical 

Processing Plant (CPP) (e.g., at least one film 

badge or TLD dosimeter from CPP) between 

January 1, 1975, and December 31, 1980, for 

a number of work days aggregating at least 

250 work days, occurring solely under this 

employment, or in combination with work 

days within the parameters established for 

one or more other classes of employees in the 

Special Exposure Cohort. 

This designation became effective on 

December 22, 2017. Therefore, 

beginning on December 22, 2017, 

members of this class of employees, 
Adjuvant Discovery & Development for 

Allergic Diseases. 

Date: February 23, 2018. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract

proposals. 

Place: National Institutes of Health, 5601

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Dharmendar Rathore, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, Room 3G30, National Institutes 

Health/NIAID, 5601 Fishers Lane Drive, M

9823, Bethesda, MD 20892–9823, 240–669–

5058, rathored@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HH

Dated: January 23, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory

Committee Policy. 

[FR Doc. 2018–01486 Filed 1–25–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

o

SC

, 

S

f

)


daltland on DSKBBV9HB2PROD with NOTICES

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01). 

Date: February 20, 2018. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892 

(Telephone Conference Call). 

Contact Person: Brenda Lange-Gustafson, 

Ph.D., Scientific Review Officer, NIAID/NIH/ 

DHHS, Scientific Review Program, 5601 

Fishers Lane, Room 3G13, Rockville, MD 

20852, 240–669–5047, bgustafson@ 

niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Applications (P01). 

Date: February 21–23, 2018. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health. 5601 

Fishers Lane, Rockville, MD 20892. 

Contact Person: Priti Mehrotra, Ph.D., 

Chief, Immunology Review Branch, Scientific 

Review Program, Division of Extramural 

Activities, Room #3G40, National Institutes 

of Health/NIAID, 5601 Fishers Lane, MSC 

9823, Bethesda, MD 20892–7616, 240–669– 

5066, pmehrotra@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; PHS 2018–1 Topic 54 & 55: 

Fe

a

fol

pu

pr

55

as 

th

co

pr

an

in

ap

w

in

Bi

Sp

De

A

ap

De

Pl

Sc

Bo

Be

jo

Frm 00077

Name of Committee: National Institute of 

Pursuant t

deral Adv

mended, n

lowing m

The meeti

blic in ac

ovisions s

2b(c)(4) a

amended.

e discussi

nfidential 

operty suc

d persona

dividuals 

plications

ould const

vasion of 

Name of Co

omedical I

ecial Emph

velopment 

ward Applic

Date: March

Time: 9:30 

Agenda: To 

plications. 

Place: Natio

mocracy Pl

aza, Bethes

Contact Per

ientific Rev

ulevard, Ro

thesda, MD

hn.holden@

Fmt 4703 Sfmt 4703 E:\FR\FM\26JAN1.SGM 26JAN1

invasion of personal privacy. Imaging and Bioengineering; Notice of 

Closed Meeting 

o section 10(d) of the

isory Committee Act, as 

otice is hereby given of the 

eeting. 

ng will be closed to the 

cordance with the 

et forth in sections 

nd 552b(c)(6), Title 5 U.S.C., 

 The grant applications and 

ons could disclose 

trade secrets or commercial 

h as patentable material, 

l information concerning 

associated with the grant 

, the disclosure of which 

itute a clearly unwarranted 

personal privacy. 

mmittee: National Institute of 

maging and Bioengineering 

asis Panel; Mentored Career 

(K) and Conference (R13)

ation Review, (2018/05).

 2, 2018.

a.m. to 5:00 p.m.

review and evaluate grant

nal Institutes of Health, Two

aza, Suite 920, 6707 Democracy

da, MD 20892 (Virtual Meeting).

son: John P. Holden, Ph.D.,

iew Officer, 6707 Democracy

om 920, Democracy Two,

 20892, (301) 496–8775,

mail.nih.gov.

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Fellowships in 

Digestive Diseases and Nutrition. 

Date: February 15–16, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Jian Yang, Ph.D., Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

7111, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7799, yangj@ 

extra.niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; PAR–16–034: 

NIDDK Ancillary Studies to Major Ongoing 

Clinical Studies in Digestive Sciences (R01). 

Date: February 15, 2018. 

Time: 2:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Najma S. Begum, Ph.D., 

Scientific Review Officer, Review Branch, 

DEA, NIDDK, National Institutes of Health, 

Room 7349, 6707 Democracy Boulevard, 

Bethesda, MD 20892–5452, (301) 594–8894, 

begumn@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

applications, the disclosure of which 

would constitute a clearly unwarranted National Institute of Biomedical 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Federal Register / Vol. 83, No. 18 / Friday, January 26, 2018 / Notices 3749 

defined as reported in this notice, 

became members of the SEC. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2018–01449 Filed 1–25–18; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

Dated: January 23, 2018. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–01488 Filed 1–25–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which